Replimune Group (NASDAQ: REPL)

2d ago, source: The Motley Fool

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates ...

REPL Replimune Group, Inc.

4d ago, source: Seeking Alpha

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic ...

Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

5mon ago, source: Hosted on MSN

Replimune Group Inc. shares dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in ...

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1mon ago, source: Yahoo Finance

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies.

Replimune Group Inc REPL

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1mon ago, source: Finanznachrichten

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic ...

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1mon ago, source: ADVFN

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the grant of inducement ...

Replimune Group Inc (REPL)

4d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Replimune Group Inc.

7mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...